Abstract
This chapter reviews the structural requirements for H2 agonists and antagonists. Section B discusses the agonists, which are divided into three classes: the non-selective histamine analogues, showing H2 activity as well as H1 and H3 activity; dimaprit, a selective, but moderately active agonist which allows no substitution without a dramatic fall in activity; and, thirdly, the impromidine-related compounds including very potent H2 agonists, some of which also show Η1 antagonism and some are rather potent H3 antagonists as well. Section C reviews more than 1000 different H2 antagonists; these compounds belong to rather different classes of compounds. It is therefore clear that the structural requirements for H2 antagonism are much less restrictive than might have been originally thought. Finally, in Section D the structural requirements for interference with the P-450 enzyme(s) are summarized. The inhibitory effects of H2 antagonists on the P-450-mediated metabolic pathways are probably the cause of the major side effects of some H2 antagonists. This interaction may lead to a less extensive metabolism of certain other drugs, given together with H2 antagonists interfering with P-450. As was to be expected, it has been found that this inhibitory effect is related neither to the potency of these H2 antagonists nor to the general structural features which determine affinity for the H2 receptors.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adger BM, Lewis NJ (1985) Chemical process. European patent 141560, 15 May
Agrawal VK, Knaus EE, McNeil JH (1987) Pyridine and reduced pyridine analogues of 1,2,5-thiadiazoles as histamine H2-receptor antagonists. Eur J Med Chem 22:319–323
Algieri AA (1984) 2,5-Disubstituees-4(3H)-pyrimidones. Belgian patent 900652, 2 Sept
Algieri AA, Luke GM, Standridge RT, Brown M, Partyka RA, Crenshaw RR (1982) 1,2,5-Thiazole 1-oxide and 1,1-dioxide derivatives. A new class of potent histamine H2-receptor antagonists. J Med Chem 25(3):210–212
Allen RM, Fletcher SR (1986) Benzodioxine and benzoxazine derivatives. British patent 2174705 A, 12 Nov
Anglada L, Marquez M, Sacristan A, Ortiz JA (1988) Inhibitors of gastric secretion: N-sulphonylformamidines in a series of new histamine H2-receptor antagonists. Eur J Med Chem 23:97–100
Armstrong JM, Duval N, Langer SZ (1983) LY 141865 stimulates histamine-2 (H2) receptors and dopamine-2 (DA2) receptors in the anaesthetised dog. Eur J Pharmacol 87:165–166
Arrang JM, Garbarg M, Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302:832–837
Arrigoni C, Castello R, Ceserani R, de Castiglione R, Lazzarini AM, Scarponi U, Toti D, Vahgi F (1985) Antisecretory and antiulcer effect of a potent H2-antagonist: FCE 23067. Br J Pharmacol 86:780 P
Barzen R, Schunack W (1980) Synthese und Wirkung N-substituierter 4-[(2-amino-ethylmercapto)-methyl]-imidazole. Arch Pharm (Weinheim) 313:544–549
Barzen R, Schunack W (1981) Synthese und H2-antihistaminische Wirkung Ν,Ν’-substituierter Thioharnstoffe, Cyanoguanidine und Bithiooxamide. Arch Pharm (Weinheim) 314:617–622
Barzen R, Schunack W (1982) Keten-N, N-acetale mit H2-antihistaminischer Wirkung. Arch Pharm (Weinheim) 315:680–684
Bast A (1986) The formation of reactive oxygen by cytochrome P-450, perilous and predictable? Trends Pharmacol Sci 7:266–270
Bast A, Savenije-Chapel EM, Kroes BH (1984) Inhibition of mono-oxygenase and oxidase activity of rat-hepatic cytochrome P-450 by H2-receptor blockers. Xeno-biotica 14:399–408
Bast A, Smid K, Timmerman H (1989) The effects of cimetidine, rantidine and famotidine on rat hepatic microsomal cytochrome P-450 activities. Agents Actions 27:188–191
Batzri S, Harmon JW, Toles R (1983) Comparison of cimetidine with new H2-antagonists in rabbit and guinea-pig gastric cells. Eur J Pharmacol 94:1–8
Batzri S, Thompson WF, Toles R (1985) Distortion of H2-antagonist equilibrium constants by uptake in rabbit gastric mucosal cells. Pharmacology 30:215–244
Baumann G (1982) Arzneimittel zur Behandlung von chronischem und akutem Herzversagen. German patent DE 3239870, 27 Oct
Baumann G, Felix SB, Heidecke CD, Riess G, Loher U, Ludwig L, Blömer H (1984) Apparent superiority of H2-receptor stimulation and stimultaneous β-blockade over conventional treatment with β-sympathomimetic drugs in post-acute myocardial infarction. Agents Actions 15:216–228
Bays DE, Price BJ (1985) The development of H2-receptor antagonists with an extended duration of action. In: Dahlbom R, Nilsson JLG (eds) Proceedings Vlllth International Symposium on Medicinal Chemistry, vol 2. Swedish Pharmaceutical Press, Stockholm pp 183–195
Bays DE, Hayes R, Blatcher P, Adkinson M (1984) Guanidinoazolyl derivatives as histamine H2 antagonists. European patent 0117368, 5 Sept
Bertaccini G, Coruzzi G, Scarpignato C (1981) Effects of alkyl analogs of histamine and metiamide on the isolated guinea-pig heart. Pharmacology 22:101–107
Bertaccini G, Poli E, Coruzzi G (1984) Action of the new H2-antagonist, DA 4577, on different in vitro and in vivo preparations. Agents Actions 14:510–515
Bertaccini G, Coruzzi G, Poli E, Adami M (1986) Pharmacology of the novel H2-antagonist famotidine: in vitro studies. Agents Actions 19:180–187
Bickel M, Herling AW, Rising TJ, Wirth K (1986) Antisecretory effects of two new histamine H2-receptor antagonists. Arzneimittel-Forschung 36:1358–1363
Bietti G, Cereda E, Giachetti A, Micheletti R, Bast A, Timmerman H, Donetti A (1988) Are the imidazoles of cimetidine and mifentidine bioisostere? Eur J Med Chem 23:267–273
Black JW, Duncan WAM, Durant GJ, Ganellin CR, Parsons EM (1972) Definition and antagonism of histamine H2-receptors. Nature 236:385–390
Black JW, Duncan WAM, Emmett JC, Ganellin CR, Hesselbo T, Parsons ME, Wyllie JH (1973a) Metiamide-an orally active histamine H2-receptor antagonist. Agents Actions 3:133–137
Black JW, Durant GJ, Emmett JC, Ganellin CR (1973b) Isothioureas and their derivatives. US patent 3,759,944, 18 July
Black JW, Durant GJ, Emmett JC, Ganellin RC (1974) Sulphur-methylene isosterism in the development of metiamide, a new histamine H2-receptor antagonist. Nature 248:65–67
Blakemore RC, Brown TH, Durant GJ, Ganellin CR, Parsons ME, Rasmussen AC, Rawlings DA (1981) SK & F 93479, a potent and long-acting histamine H2-receptor antagonist. Br J Pharmacol 74:200P
Blakemore RC, Brown TH, Chenery RJ, Durant GJ, Ganellin CR, Parsons ME, Rasmussen AC, Rawlings DA (1985) SK & F 93574 a potent and long acting histamine H2-receptor antagonist for intravenous administration. Br J Pharmacol 86:570P
Blakemore RC, Ganellin CR, Leigh BK, Parsons ME, Price CA, Smith IR, Tertiuk W (1986) N-Methyldimaprit (SK & F 92054). A chemical control for the histamine H2-receptor agonist dimaprit. Agents Actions 19:18–25
Bonjean J, Schunack W (1987a) Synthese und H2-antagonistische Wirkung imidazolyl-methylthioalkyl-substituierter 1,2,4-Triazole. Arch Pharm (Weinheim) 320:554–562
Bonjean J, Schunack W (1987b) Isolamtidin und Analoge. Arch Pharm (Weinheim) 320:608–616
Bonjean J, Schunack W (1988) Alkylund Alkoxy-substituierte Lamtidin-Analoge: Synthese und H2-antagonistische Aktivität. Arzneimittel forschung 38(7):501–507
Borchers A, Schunack W (1984) Synthese und H2-antihistaminische Wirkung Nα-substituierter Histamine. Arch Pharm (Weinheim) 317:455–459
Borchers A, Engler H, Selenyi I, Schunack W (1982) Synthese und H2-antihistaminische Wirkung N,Ν’-bisimidazol-substiuierter Thioharnstoffe, Cyano-guanidine und 2-Nitro-l, l-ethendiamine. Arzneimittel forschung 32(12):1509–1512
Borchers A, Büyüktimkin N, Schunack W (1983) Synthesis and H2-antihistaminic activity of α-methylated cimetidine analogs. Sci Pharm 51:3–8
Borella L, Russel J, Rimele TJ, Grimes D, Failli A, Mir GN (1988) Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action. Arzneimittel forschung 38:366–372
Borm P, Bast A, Frankhuijzen-Sierevogel A, Noordhoek J (1981) Cytochrome P-450 and ethoxycoumarin-deethylation in rat gastric microsomes: induction by 3-methylcholanthrene and inhibition by cimetidine. Biochem Biophys Res Commun 102:784–790
Bottomley KMK, Rising TJ, Steward A (1985) Relative efficacies of histamine H2-receptor agonists in the guinea-pig right atrium. Br J Pharmacol 84:47P
Boyd EJS, Wormsley KG (1984) Effect of loxtidine, a new histamine H2-receptor antagonist, on 24-hour gastric secretion in man. Eur J Clin Pharmacol 26:443–447
Bradshaw J, Brittain RT, Clitherow JW, Daly MJ, Price BJ, Stables R (1979) Rantidine (AH 19065): a new potent, selective histamine H2-receptor antagonist. Br J Pharmacol 66:464P
Bradshaw J, Butcher ME, Clitherow JW, Dowle MD, Hayes R, Judd DB, McKinnon JM, Price BJ (1982) Aminoalkylfurans as H2-receptor antagonist. In: Creighton AM, Turner S (eds) The chemical regulation of biological mechanism. The Royal Society of Chemistry, London, pp 45–57
Brimblecombe RW, Duncan WAM, Durant GJ, Emmett JC, Ganellin CR, Parsons ME (1975) Cimetidine. Nonthiourea histamine H2-receptor antagonist. J Int Med Res 3:86–92
Brittain RT, Jack D, Price BJ (1981) Recent developments in histamine H2-antagonists. Trends Pharmacol Sci 2:310–313
Brittain RT, Jack D, Reeves JJ, Stables R (1985) Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an unsurmountable histamine H2-receptor blocking drug. Br J Pharmacol 85:843–847
Brown T (1984) Aminoimidazolone derivatives as histamine H2-antagonists. Patent Cooperation Treaty W084/04304, 8 Nov
Brown TH, Rawlings DA (1983) Aminopyrimidones as histamine H2-antagonists. European Patent 0117345, 29 Nov
Brown TH, Tuddenham D (1985) Verfahren zur Herstellung von 5-Aminopyrimidin-4-on Verbindungen und ihren Salzen. East German patent 216933 A5, 2 Jan
Brown TH, Durant GJ, Emmett JC, Ganellin CR (1976) Pyrimidone and thiopyrimi-done derivatives. British patent 1595291, 21 Sept
Brown TH, Blakemore RC, Durant GJ, Emmett JC, Ganellin RC, Parsons ME, Rawlings DA, Walker TF (1988) Isocytosine H2-receptor histamine antagonists I. Oxmetidine and related compounds. Eur J Med Chem 23:53–62
Brown TH, Blakemore RC, Blurton P, Durant GJ, Ganellin RC, Parsons ME, Rasmussen AC, Rawlings DA, Walker TF (1989) Isocytosine H2-receptor histamine antagonists II. Synthesis and evaluation of biological activity at histamine H1and H2-receptors of 5-(heterocyclyl)methylisocytosines. Eur J Med Chem 24:65–72
Buck SH, Yellin TO, Mant DH (1979) ICI 17148: a new H2-receptor blocker. Pharmacologist 21:265
Burger A, Bernabe M, Collins PW (1970) 2-(4-Imidazolyl)cyclopropylamine. J Med Chem 13:33–35
Buschauer A (1987a) Synthese und pharmakologische Wirkung substituierter Imida-zolylund Thiazolylmethylthioethylguanidine. Arzneimittel forschung 37:1003–1007
Buschauer A (1987b) Synthese und pharmakologische Wirkung von Arylmethyl-thioethylguanidinen. Arzneimittel forschung 37:1008–1012
Buschauer A (1988a) Synthese positiv inotroper Substanzen: Aryloxyalkylguanidine. Arch Pharm (Weinheim) 321:281–285
Buschauer A (1988b) Synthese positiv inotroper Substanzen: Imidazolylpropyl-guanidine mit Pyridin-Partialstruktur. Arch Pharm (Weinheim) 321:415–418
Buschauer A (1988c) Phenoxyand phenylthioalkylguanidines: synthesis and in vitro pharmacology. Eur J Med Chem 23:1–6
Buschauer A (1988d) Imidazolylalkylguanidine mit Diaryl-Partialstrukturen. Sci Pharm 56:81–88
Buschauer A (1988e) Synthesis and structure-activity relationships in a series of H2-agonistic guanidines with positive inotropic activity. Poster Xth International Symposium on Medicinal Chemistry, Budapest.
Buschauer A (1989) Synthesis and in vitro pharmacology of arpromidine and related phenyl (pyridylalkyl) guanidines, a potential new class of positive inotropic drugs. J Med Chem 32:1963–1970
Buschauer A, Wegner K, Schunack W (1982) Basisch substituierte Cimetidin- Analoge. Eur J Med Chem 17:505–508
Buschauer A, Postius S, Szelenyi I, Schunack W (1985) Isohistamine und Homologe als Bausteine von H2-Antagonisten. Arzneimittel forschung 35(7): 1025–1029
Buschauer A, Krämer I, Schunack W (1986a) Synthese und H2-antagonistische Wirkung 3-(3-Piperidinomethylphenoxy)-propyl-substituierter Kohlensäurederivate und Analoge. Arch Pharm (Weinheim) 319:434–443
Buschauer A, Schickaneder H, Mörsdorf P, Schunack W, Baumann G, Ahrens KH (1986b) Neue Imidazolylguanidinderivate, Verfahren zu ihrer Herstellung und diese Verbindingen enthaltende Arzneimittel. German patent 3631334 Al, 15 Sept
Buschauer A, Schunack W, Arrang JM, Garbarg M, Schwartz JC, Young JM (1989) Histamine receptors. In: Williams M, Glennon RA, Timmermans PMWM (eds) Receptor pharmacology and function, Dekker, New York, pp 293–348
Buyniski JP, Cavanagh RL, Gordon M (1984a) Pharmaceutical compositions. European patent 0099122, 25 Jan
Buyniski JP, Cavanagh RL, Pircio AW, Algieri AA, Crenshaw RR (1984b) Structure-activity relationship among newer histamine H2-receptor antagonists. In: Mel-chiorre C, Giannella M (eds) Highlights in receptor chemistry. Elsevier, Amsterdam, pp 195–213
Büyüktimkin S, Buschauer A, Schunack W (1989) Synthese und in vitro Pharmakologie von 2-Aryl-l-{[3-(imidazol-4-yl)propyl]-guanidinoalkyl}-2,3-dihydro-4(lH)-chinazolinonen. Arch Pharm (Weinheim) 322:115–118
Calcutt CR, Ganellin CR, Griffiths R, Leigh BK, Maguire JP, Mitchell RC, Mylek ME, Parsons ME, Smith IR, Young RC (1988) Zolantidine (SK & F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist. Br J Pharmacol 93:69–78
Cavanagh RL, Usakewicz JJ, Buyniski JP (1983) A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, rantidine and tiotidine. J Pharm Exp Pharmacol 224:171–179
Comisso G, Toso R, Gratton G et al. (1979) Synthesis and ulcerostatic activity of l-cyano-2-methyl-3-[2-(4-methyloxazol-5-yl]-guanidine. Acta Pharm Jugosl 29:125–130
Coombes JD, Norris DB, Rising TJ, Ross BC, Steward A (1985a) In vitro histamine H2-antagonist activity of the novel compound HUK 978. Life Sci 37:1711–1718
Coombes JD, Norris DB, Rising TJ, Ross BC, Steward A (1985b) Anti-secretory activity of the novel H2-antagonist, HUK 978, in rat, guinea-pig and dog. Life Sci 37:1719–1726
Coruzzi G, Poli E, Bertaccini G (1983) Cardiac effects of the new H2-receptor antagonists. Agents Actions 13:173–178
Coruzzi G, Adami M, Bertaccini G (1984) Action of histamine and some H2-antagonists on gastric secretion “in vitro”. Agents Actions 14:516–521
Coruzzi G, Bertaccini G, Noci MT, Dobrilla G (1986) Inhibitory effect of famotidine on cat gastric secretion. Agents Actions 19:188–193
Crenshaw RR, Luke GM (1982) N’’-Cyano-N’-{2-{4-methyl-5-imidazolyl)methylthio}ethyl}-N”-alkynylguanidines H2 receptor blocking agents. Canadian patent 1130360, 24 Aug
Crenshaw RR, Algieri A A (1983) 3,4-Diamino-1,2,5-thiadiazoles substitués possé-dante une activité antagoniste du récepteur-H2 de l’histamine. Belgian patent 896.291, 28 Sept
Crenshaw RR, Algieri AA, Buyniski JP, Cavanagh RL, Gordon M (1983) Pharmaceutical compositions. European patent 0099121 A2, 12 July
Defilippi A, Sorba G, Calvino R, Garrone A, Gasco A, Orsetti M (1988) Potential histamine H2-receptor antagonists: analogues of classical antagonists containing 4-substitued-3-aminofurazan moieties. Arch Pharm (Weinheim) 321:77–80
Donetti A (1988) Medicinal chemistry in the H2-receptor antagonist series. In: Actualités de chimie thérapeutique, series 15. Société de Chimie Thérapeutique Châtenay-Malabry:227–246
Donetti A, Cereda E, Bellora E, Gallazzi A, Bazzano C, Vanoni P, Del Soldato P, Micheletti R, Pagani F, Giachetti A (1984) (Imidazolylphenyl)-formamidines. A structurally novel class of potent histamine H2-receptor antagonists. J Med Chem 27:380–386
Donetti A, Trummlitz G, Bietti G, Cereda E, Bazzano C, Wagner H-U (1985) Conformational studies of two histamine H2-receptor antagonistic phenylformamidines: mifentidine and its guanidinothiazole analogue DA 4643. Arzneimittel forschung 35:306–315
Donné-Op den Kelder GM, Haaksma EEJ, Van der Schaar MWG, Veenstra DMJ, Timmerman H, Cereda E, Dubini E (1988) QSAR studies on mifentidine and related compounds. Quant Struct-Act Relat 7:60–71
Drew R, Rowell J, Grygiel JJ (1981) Cimetidine: a specific inhibitor of hepatic aryl hydrocarbon hydroxylase (AHH) in the rat. Res Commun Chem Pathol Pharmacol 33:81–93
Durant GJ (1985) Guanidine derivatives acting at histaminergic receptors. Chem Soc Rev 14:375–398
Durant GJ, Parsons ME, Black JW (1975a) Potential histamine H2-receptor antagonists. 2. Nα-guanylhistamine. J Med Chem 18:830–833
Durant GJ, Ganellin CR, Parsons ME (1975b) Chemical differentation of histamine H1- and H2-receptor agonists. J Med Chem 18:905–909
Durant GJ, Emmett JC, Ganellin CR, Miles PD, Parsons ME, Prain HP, White GR (1977) Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine. J Med Chem 20:901–906
Durant GJ, Duncan WAM, Ganellin CR, Parsons ME, Blakemore RC, Rasmussen AC (1978) Impromidine (SK & F 92676) is a very potent and specific agonist for histamine H2 receptors. Nature 276:403–405
Durant GJ, Ganellin CR, Hills DW, Miles PD, Parsons ME, Pepper ES, White GR (1985) The histamine H2-receptor agonist impromidine: synthesis and structure-activity considerations. J Med Chem 28:1414–1422
El-Badry OM, Knaus EE, McNeil JH (1985a) Pyridine and reduced pyridine analogues as histamine H2-receptor antagonists. Eur J Med Chem 20:403–407
El-Badry OM, Knaus EE, McNeil JH (1985b) Pyridine and reduced pyridine analogues of ranitidine as histamine H2-receptor antagonists. Eur J Med Chem 20:409–413
El-Badry OM, Knaus EE, McNeil JH (1987) Pyridine and reduced pyridine analogues of cimetidine as histamine H2-receptor antagonists. Eur J Med Chem 22:579–582
Elz S, Schunack W (1987) Darstellung und H2-agonistische Aktivität alkylsubstituierter 3-(Imidazol-4-yl)propylguanidine. Arch Pharm (Weinheim) 320:182–185
Elz S, Schunack W (1988a) H2-antagonistische Aktivität Impromidin-analoger Cyano-guanidine. Arzneimittel forschung 38:7–10
Elz S, Schunack W (1988b) Impromidin-analoge Guanidine: Synthese und Wirkung am Histamin-H2-receptor. Arzneimittel forschung 38:327–332
Elz S, Kimmel U, Schunack W (1988a) H2-Agonistisch wirksame co-[l-(Imidazol-4-yl)ethylthio]alkylguanidine und Benzylanaloge. Sci Pharm 56:65–71
Elz S, Kimmel U, Buschauer A, Schunack W (1988b) Halogenderivate von N-[3-(Imidazol-4-yl)propyl]-N’-(2-phenylthioalkyl)guanidine mit H2-agonistischer Aktivität. Sci Pharm 56:229–234
Emmett JC, Durant GJ, Ganellin RC, Roe AM, Turner JL (1982) Potential histamine H2-receptor antagonists. 4. Benzylhistamines. J Med Chem 25:1168–1174
English TAM, Gristwood RW, Owen DAA, Wallwork J (1986) Impromidine is a partial histamine H2-receptor agonist on human ventricular myocardium. Br J Pharmacol 89:335–340
Failli A, Borella L (1983) Thiadiazolediamine derivatives with histamine H2-receptor inhibiting properties. US patent 4529731, 22 Sept
Feely J, Wilkinson GR, Wood AJJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304:692–695
Festal D, Descours D, Depin J-C, Quentin Y (1986) Dérivés de thiéno et furo-[2,3-c]pyrroles, procédés de preparation et médicaments les contenant. French patent 2571723, 18 April
Gajtkowski GA, Norris DB, Rising TJ, Wood TP (1983) Specific binding of 3H-tiotidine to histamine H2-receptors in guinea-pig cerebral cortex. Nature 304:65–67
Ganellin CR (1978) Selectively and the design of histamine H2-receptor antagonists. J Appl Chem Biotechnol 28:183–200
Ganellin CR (1981) Medical chemistry and dynamic structure-activity analysis in the discovery of drugs acting at histamine H2-receptors. J Med Chem 24:913–920
Ganellin CR (1982a) Chemistry and structure-activity relationships of drugs acting at histamine receptors. In: Ganellin CR, Parsons ME (eds) Pharmacology of histamine receptors. Wright, Bristol, pp 10–102
Ganellin CR (1982b) Characterization and distribution of histamine receptors. In: Creighton AM, Turner S (eds) The chemical regulation of biological mechanisms. Royal Society of Chemistry, London, pp 1–15
Ganellin CR, Durant GJ, Emmett JC, Hills DW, Ife RJ, Miles PD, Parsons ME (1985) Recent structure-activity studies of H2-receptor histamine antagonists. In: Dahlbom R, Nilsson JLG (eds) Proceedings VIIIth International Symposium on Medicinal Chemistry, vol 2. Swedish Academy of Pharmaceutical Sciences, Stockholm, pp 153–168
Ganellin CR, Blakemore RC, Brown TH, Cooper DG, Durant GJ, Harvey CA, Ife RJ, Owen DAA, Parsons ME, Rasmussen AC, Sach GS (1986) Icotidine, an antagonist of histamine at both Η1 and H2 receptors. N Engl Reg Allergy Proc 7:126–133
Ganellin CR, Mitchell RC, Young RC (1988) Recent structure-activity studies with antagonists at histamine H2 receptors. In: Melchiorre C, Giannella M (eds) Recent advances in receptor chemistry. Elsevier, Amsterdam, pp 289–306
Garg DC, Weider DJ, Jallad NS (1982) The effects of ranitidine and cimetidine on hepatic blood flow. Clin Pharmacol Ther 31:228–229
Gater PR, Webber SE, Gui GPH, Jordan CC, Haye NA, Ashford JJ, Foreman JC (1986) Some studies of the action of betahistine at Η1 and H2 receptors for histamine. Agents Actions 18:342–350
Gerber MC, Tejwani GA, Gerber N, Bianchine JR (1985) Drug interactions with cimetidine: an update. Pharmacol Ther 27:353–370
Gerhard G, Schunack W (1980a) Struktur-Wirkungs-Beziehungen bei Histaminanaloga, 20. Mitt. Absolute Konfiguration und histaminartige Wirkung der enantiomeren α-Methylhistamine. Arch Pharm (Weinheim) 313:709–714
Gerhard G, Schunack W (1980b) Struktur-Wirkungs-Beziehungen bei Histaminanaloga, 22. Mitt. Absolute Konfiguration und histaminartige Wirkung der enantiomeren αNα-Dimethylhistamine. Arch Pharm (Weinheim) 313:780–784
Gerhard G, Schunack W (1981) Struktur-Wirkungs-Beziehungen bei Histaminanaloga, 23. Mitt. Absolute Konfiguration and histaminartige Wirkung der enantiomeren a-Chlormethylhistamine and Nα-Methyl-a-chlormethylhistamine. Arch Pharm (Weinheim) 314:1040–1045
Gespach C, Menez I, Emami S (1983) Potent and specific blockade by AH 22216 of histamine-H2-receptor-mediated acid secretion in isolated rabbit gastric cells. Biosci Rep 3(9):871–878
Giachetti A, Pagani F, Micheletti R, Brambilla A, Cereda E, Donetti A (1985) Pharmacological profile of mifentidine: a novel H2-receptor antagonist. Agents Actions 16:173–175
Gilman DJ, Jones DF, Oldham K, Wardleworth JM, Yellin TO (1982) 2-Guanidinothiazoles as H2-receptor antagonists. In: Creighton AM, Turner S (eds) The chemical regulation of biological mechanism. Royal Society of Chemistry, London, pp 58–76
Grant SM, Langtry HD, Brogden RN (1989) Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37:801–870
Grechishkin LL, Goldjarb VL, Gavrovskaya LK (1977) Effect of derivatives of 3-(β-aminoethyl)-l,2,4-triazole on the histamine H1- and H2-receptors. Pharmacology 15:512–518
Harada M, Terai M, Maeno H (1983) Effect of a new potent H2-receptor antagonist 3-[2-[(diaminomethylene)amino]-4-thiazolyl]methylthio]-N2-sulfamoylpropion-amidine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea-pig. Biochem Pharmacol 32:1635–1640
Harvey CA, Owen DAA (1984) Cardiovascular studies with SK & F 93319, an antagonist of histamine at both H1- and H2-receptors. Br J Pharmacol 83:427–432
Henry DA, Somerville KW, Kitchingman GK, Holmes IB, Tobert JA, Langman MJS (1985) L-643,411: an H2-receptor antagonist with potent and long-lasting effects in man. Br J Clin Pharmacol 20:133–136
Hepp M, Dziuron P, Schunack W (1979) Struktur-Wirkungs-Beziehungen bei Histaminanaloga, 19. Mitteilung. 2-Substituierte Histamine mit selektiv H1-agonistischer Aktivität. Arch Pharm (Weinheim) 312:637–639
Herke J, Schunack W (1979a) Synthese und H2-antihistaminische Wirksamkeit Metiamid-Analoger Sulfoxide und Sulfone. Arch Pharm (Weinheim) 312:35–39
Herke J, Schunack W (1979b) Synthese und H2-antihistaminische Wirkung Metiamid-und Cimetidin-analoger Ether. Eur J Med Chem 14:203–206
Hill SJ (1987) Histamine receptors in the mammalian central nervous system: biochemical studies. In: Ellis GP, West GB (eds) Progress in medicinal chemistry, vol 24. Elsevier, Amsterdam, pp 29–84
Hoffman JM, Pietruszkiewicz AM, Habecker CN, Phillips BT, Bolhofer WA, Cragoe EJ Jr, Torchiana ML, Lumma WC Jr, Baldwin JJ (1983) Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidine. J Med Chem 26:140–144
Höltje H-D, Baranowski P, Spengler JP, Schunack W (1985) Ein Bindungsstellenmodell für H2-Antagonisten vom 4-Pyrimidinon-Typ. Arch Pharm (Weinheim) 318:542–548
Ife RJ, Catchpole KW, Durant GJ, Ganellin CR, Harvey CA, Meeson ML, Owen DAA, Parsons ME, Slingsby BP, Theobald CJ (1989) Non-basic histamine H1-antagonists. I. Synthesis and biological evaluation of some substituted 2-(2-pyridylaminoalkylamino)pyrimidones and related compounds. Eur J Med Chem 24:249–258
Impicciatore M, Chiavarini M, Razzetti R, Plazzi PV (1980) Stimulation of acid and pepsin secretions in fistula cat by dimaprit-like compounds. Farmaco [Sci] 35:418–424
Impicciatore M, Morini G, Chiavarini M, Plazzi PV, Bordi F, Vitali F (1986) Pharmacological activities of two new histamine analogs. Agents Actions 18:134–136
Impicciatore M, Morini G, Chiavarini M, Barocelli E, Bordi F, Plazzi PV, Vitali F (1987) Are histamine receptors involved in the stimulant activities of thiazolylethy-lamines supposed as cyclic models of dimaprit? Agents Actions 20:262–264
Ioannoni B, Mason SR, Reilly PEB, Winzor DJ (1986) Evidence of induction of hepatic microsomal cytochrome P-450 by cimetidine: Binding and kinetic studies. Arch Biochem Biophys 247:372–383
Ishikawa T, Kamaisaki Y, Itoh T (1989) Pharmacological properties of the hydroxy-lated histamine (±)-4(5)-(2-amino-l-hydroxyethyl)-imidazole. Agents Actions 26:261–266
Ito Y, Noguchi T, Naito H (1985) Fluorometric determination of gizzerosine, a histamine H2-receptor agonist discovered in feedstuffs, employing highperformance liquid chromatography. Anal Biochem 151:28–31
Jackson JE (1982) Cimetidine protects against acetaminophen toxicity. Life Sci 31:31–35
Jensen JC, Gugler R (1985) Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol. 34:2141–2146
Katz LB, Scott CK, Shriver DA (1986a) Pharmacology of ORF17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine. J Pharmacol Exp Ther 237:404–410
Katz LB, Scott CK, Shriver DA (1986b) Pharmacological comparison of ORF17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine. J Pharmacol Exp Ther 238:587–593
Keller F, Buschauer A, Schunack W (1988a) Synthesis, resolution and activity of chiral histamine H2-antagonists. Proceedings Xth international symposium on medicinal chemistry, Budapest, p 229
Keller F, Buschauer A, Schunack W (1988b) Synthese, Racemattrennung und pharmakologische Wirkung chiraler Histamin H2-Antagonisten vom Aminomethylphe-noxyalkylamin-Typ. Pharm Z Wiss 1:48–55
King FD, Fake CS, Burrell G (1982) Histamine H2-receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series. European patent 0105 732, 1 Oct
Klotz U, Reimann I (1984) Drug interactions through binding to cytochrome P-450: the experience with H2-receptor blocking agents. Pharm Res 2:59–62
Klotz U, Arvela P, Pasanen M, Kroemer H, Pelkonen O (1987) Comparative effects of H2-receptor antagonists on drug metabolism in vitro and in vivo. Pharmacol Ther 33:157–161
Knodell RG, Holtzman JL, Crankshaw DL, Steele NM, Stanley LN (1982) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology 82:84–88
Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V (1987) The excitatory effect of the new histamine H2-receptor antagonist nizatidine (LY 139037) on the guinea-pig ileum. J Pharmacobiodyn 10:669–672
Krämer I, Schunack W (1985) Synthese und H2-antagonistische Wirkung mono-substituierter 1,2,4-Oxadiazol-3,5-diamine. Arch Pharm (Weinheim) 318:888–895
Krämer I, Schunack W (1986a) Synthese und H2-antagonistische Wirkung N3, N5-substituierter 1,2,4-Oxadiazol-3,5-diamine. Arzneimittel forschung 36:1011–1014.
Krämer I, Schunack W (1986b) Synthese und H2-antagonistische Wirkung Ν,Ν’-substituierter 1,3,4-Oxadiazol-2,5-diamine. Arzneimittel forschung 36: 1564–1567
Krämer I, Schunack W (1986c) Synthese und H2-antagonistische Wirkung von N-[3-(3-Piperidinomethyl-phenoxy)propyl]-l,3,4-oxadiazol-2-aminen. Arch Pharm (Weinheim) 319:1091–1098
Krämer I, Wegner K, Schunack W (1985) Synthese und H2-antagonistische Wirkung monound bisfunktionalisierter Hydrazine. Pharm Z Sci Ed 130:2062–2066
Krämer I, Szelenyi I, Schunack W (1987) 1,3,4-Oxadiazol-2,5-diamine mit H2-antagonistischer Aktivität. Arch Pharm (Weinheim) 320:120–130
Krishna DR, Klotz D (1988) Newer H2-receptor antagonists clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 15:205–215
Kuhla DE, Campbell HF, Studt WL, Neuenschwander KW (1986) Bicyclic benzo-oxyheterocyclic ethers and thioethers as H2-receptor antagonists. European patent 0198918, 9 May
Laferla G, Buchanan N, Hearns J, Crean GP, McColl KEL, Clucas AT (1986) The antisecretory effects of zaltidine, a novel long-acting H2-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer. Br J Clin Pharmacol 2:395–399
LaMattina JL, Lipinski CA (1982) 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them. European patent 50,458, 28 April
LaMattina JL, Lipinski CA (1983) Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)-thiazoles and process therefor. European patent 0094191 Al, 4 May
Lavezzo A, Manzoni L, Aureggi G, Nisato D, Bianchetti A, Carminati P (1984) In vivo and in vitro effects of CM 57555, a new antisecretory agent acting on histamine H2-receptors. Int J Tissue React 6:155–165
Lee RM, McDowall RD (1986) Recent advances in pharmaceutical chemistry. Histamine H2-receptor antagonists. J Clin Hosp Pharm 11:389–408
Lennard MS, Crewe HK, Tucker GT, Woods HF (1986) Histamine: an inhibitor of cytochrome P-450-catalysed drug metabolism. Biochem Pharmacol 35:2459–2460
Lennartz H-G, Hepp M, Schunack W (1978) Synthese und Wirkung 5-alkyl-substituierter Histamine und N α-Methyl-histamine. Eur J Med Chem 13:229–234
Leonard TB, Dent JG (1984) Effects of H2-receptor antagonists on the hepatoxicity of various chemicals. Res Commun Chem Pathol Pharmacol 44:375–388
Leonardi A, Nava G, Nardi D (1983) Sintesi di derivati benzofuranici ad actività H2 antagonista. Farmaco [Sci] 38:290–308
Lin T, Evans DE, Warrick MW, Pioch R (1987) Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. J Pharmacol Exp Ther 239:406–410
Lindstrom TD, Whitaker GW, Pioch RP (1987) Inhibition of microsomal biotransformation by a series of nitrogen and oxygen heterocyclic histamine H2-antagonists. Biochem Pharmacol 36:1669–1672
Lipinski CA (1983) Bioisosteric design of conformationally restricted pyridyltriazole histamine H2-receptor antagonists. J Med Chem 26:1–6
Lipinski CA, LaMattina JL, Hohnke LA (1985a) Pseudosymmetry and bioisosterism in biaryl pyridyl competitive histamine H2-receptor antagonists. J Med Chem 28:1628–1636
Lipinski CA, Craig RH, Wright RB (1985b) 2-amino- and 2-guanidino-4-thiazolylpyrimidines. J Heterocycl Chem 22:1723–1726
Lipinski CA, LaMattina JL, Oates PJ (1986) Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists. J Med Chem 29:2154–2163
Lumma Jr WC, Anderson PS, Baldwin JJ et al. (1982) Inhibitors of gastric acid secretion: 3,4-diamino-l,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists. J Med Chem 25:207–210
McCallum RW, Chremos AN, Kuljian B, Tupy-Visich MA, Huber PB (1985) MK-208, a novel histamine H2-receptor inhibitor with prolonged anti-secretory effect. Dig Dis Sci 30:1139–1144
Mclsaac RL, Johnston BJ, Flannery MC (1983) Dose-response curve analysis of gastric secretory responses in the dog and man to impromidine: a new histamine- H2 receptor agonist. J Pharmacol Exp Ther 225:186–190
Micheletti R, Oliva D, Belfiore P, Giachetti A, Nicosia S (1985) Evaluation of novel compounds interacting with H2-histamine receptors: effect on histamine-sensitive adenylate cyclase activity in the guinea-pig gastric muscosa. Agents Actions 16:291–294
Mitchel MC, Schenker S, Speeg KV (1984) Selective inhibition of acetaminophen oxidation and toxicity by cimetidine and other histamine H2-receptor antagonists in vivo and in vitro in the rat and in man. J Clin Invest 73:383–391
Mohr R, Buschauer A, Schunack W (1986) 1,3,5-Triazin-2,4-diamine und -2,4,6-triamine mit H2-antagonistischer Wirkung. Arch Pharm (Weinheim) 319:878–885
Mohr R, Buschauer A, Schunack W (1988) Basisch substituierte Aryloxyalkyl-guanidin-Derivate und Analoge mit H2-antagonistischer Wirkung. Arch Pharm (Weinheim) 321:221–227
Morini G, Chiavarini M, Bordi F, Plazzi PV, Vitali F, Impicciatore M (1984) H2-agonisti imidazolici: importanza della 2-amino-sostituzione per l’attività farma-cologica. Boll Soc Ital Biol Sper 40:789–795
Mörsdorf P, Schickaneder H, Herter R, Postius S, Szelenyi I, Ahrens KH (1986) Butenylderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel. German Patent 3438073 Al, 24 April
Nebert DW, Kumaki K, Sato M, Kon H (1977) Association on type I, type II and reverse type I difference spectra with absolute spin state of cytochrome P-450 iron. In: Ullrich V et al. (eds) Microsomes and drug oxidations. Pergamon, London pp 224–231
Nielsen ST (1986a) Binding of [3H]ICIA 5165, an H2-receptor antagonist to guinea-pig gastric mucosa. Agents Actions 18:524–530
Nielsen ST (1986b) H2-receptor antagonist and gastric acid antisecretory properties of WY-45 662. Agents Actions 19:158–163
Nielsen ST (1987) Characterization of the H2 receptor antagonist and gastric antisecretory properties of WY-45 727. J Pharmacol, exp Ther 242:607–613
Nielsen ST, Dove PA, Strike DP, Schieheer GA (1987) Structural modification of H2-receptor antagonists provide post-H2-receptor gastric antisecretory activity. Drugs Exp Clin Res 13:297–304
Nohara F, Fujinawa T (1986) Pyridyloxy derivatives. European patent 0177016 A2, 8 April
Norris DB, Gajtkowski GA, Wood TP, Rising TJ (1985) The use of an in vitro binding assay to predict histamine H2-antagonist activity. Agents Actions 16:170–172
Ogawa N, Yoshida T, Aratani T, Koshinaka E, Kato H, Ito Y (1988) Synthesis and histamine H2-antagonistic activity of 4-quinazolinone derivatives. Chem Pharm Bull (Tokyo) 36:2955–2967
Omura T, Sato R (1964a) The carbon monoxide-binding pigment of liver microsomes. I: Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378
Omura T, Sato R (1964b) The carbon monoxide-binding pigment of liver microsomes. II: Solubilization, purification and properties. J Biol Chem 239:2379–2385
Orsetti M, Oggero L (1988) New ranitidine analogues containing the 2-aminobenzimidazole moiety: in vivo and in vitro histamine H2-receptor blocking activity. Agents Actions 24:109–113
Orsetti M, Sorba G (1988) Pharmacological profile of new histamine H2-receptor antagonists related to cimetidine, ranitidine and lamtidine. J Pharm Pharmacol 40:31–34
Oshita M, Morikawa K. Aratani T, Kato H, Ito Y (1986) Pharmacological studies of 2-(3-(3-(l-Piperidinylmethyl)phenoxy)propylamino)-4(3H)-quinazolinone (NO-794), a new histamine H2-receptor antagonist. Jpn J Pharmacol 42:229–235
Ostersehlt B, Rieber N, Gries J (1987) 1,4-.Disubstituierte Pyrazolderivate. German patent 3532880 Al, 26 March
Owens AA, Goehring RR, Lampe JW, Erhardt PW, Lumma WC Jr, Wiggins J (1988) Cardiotonic agents 4. Dimaprit analogues as potential cardiovascular selective H2-agonists. Eur J Med Chem 23:295–300
Pagani F, Micheletti R, Brambilla A, Schiavone A, Montagna E, Ciprandi C, Giachetti A (1985) Pharmacology of mifentidine, a novel H2-receptor antagonist. Arzneimittel forschung 35:451–455
Parsons ME, Blakemore GJ, Durant GJ, Ganellin CR, Rasmussen AC (1975) 3-[4(5)-Imidazolyl]propylguanidine (SK & F 91486)-a partial agonist at histamine H2-receptors. Agents Actions 5:464
Pelkonen O, Puurunen J (1980) The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochem Pharmacol 29:3075–3080
Pendleton RG, Torchiana ML, Chung C, Cook P, Wiese S, Clineschmidt BV (1983) Studies on MK-208 (YM-11170) a new slowly dissociable H2-receptor antagonist. Arch Int Pharmacodyn 266:4–16
Pfahlert V, Mörsdorf P, Herter R, Herrlinger C, Engler H (1988) Comparison of activity of different histamine H2-agonists on resistance and capacity vessels. Arch Pharm (Weinheim) 338:R49
Pioch RP (1983) Thiazole derivatives as H2-receptor antagonists. European patent publ no 0083186 A2, 6 July
Plazzi PV, Bordi F, Impicciatore M (1985) Sulla preparazione e proprietà ista-minergiche della 2-(2-osso-4-imidazolin-4-il)etilamina. Farmaco [Sci] 40:218–220
Poli E, Medici D, Contini GA, Bertaccini G (1985) Effect of mifentidine on histamine-stimulated human atrium “in vitro”. Comparison with ranitidine and cimetidine. Arch Int Pharmacodyn 273:221–225
Postius S, Herter R, Mörsdorf P, Schickaneder H, Szelenyi I, Ahrens KH (1984) Diaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel. German Patent 3408327 Al, 7 March
Potoski JR (1984) Heterocyclic anti-ulcer agents. US patent 4458077, 3 July
Poynter D, Pick CR, Harcourt RA, Selway SAN, Harmann IW, Spurling NW, Fluck P, Cook J (1985) Association of longlasting unsurmountable histamine H2-blockade and gastric carcinoid tumours in the rat. Gut 26:1284–1295
Reeves JJ, Stables R (1987) The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643, 441 on the rat isolated gastric mucosa. Agents Actions 20:22–28
Reilly PEB, Carrington LE, Winzor DJ (1983) The interaction of cimetidine with rat liver microsomes. Biochem Pharmacol 32:831–835
Rekka E, Sterk GJ, Timmerman H, Bast A (1988) Identification of structural characteristics of some potential H2-receptor antagonists that determine the interaction with rat hepatic P-450. Chem Biol Interact 67:117–127
Rekka E, Kolstee J, Timmerman H, Bast A (1989) The effect of some H2-receptor antagonists on rat hepatic microsomal cytochrome P-450 and lipid peroxidation in vitro. Eur J Med 24:43–54
Rendic S, Sunjic V, Toso R, Kajfez F, Ruf HH (1979) Interaction of cimetidine with liver microsomes. Xenobiotica 9:555–564
Rendic S, Kajfez F, Ruf HH (1983) Characterization of cimetidine, ranitidine and related structures’ interaction with cytochrome P-450. Drug Metab Dispos 11:137–142
Riley TN, Bagley J (1984) Conformationally restricted histamine H2-receptor antagonists containing a tropane ring. US patent, 4432983, 21 Feb
Roll WD (1982) Methods and piperidinyl-alkyl-benzamide composition for inhibiting H2-histamine receptors. US patent 4310532, 12 Jan
Ross BC, Michael JD, Cousins SJ (1985) Thiatriazine derivatives. European patent 0159533 A2, 30 Oct
Rowland M, Tozer TN (1980) Clinical pharmacokinetics. Concepts and applications. Lea and Febiger, Philadelphia
Scarpignato C, Tramacere R, Tangwa M, Bertaccini G (1985) Effect of the new H2-receptor antagonist mifentidine on gastric acid secretion in the cat: comparison with cimetidine and ranitidine. Arch Int Pharmacodyn 276:142–151
Scarpignato C, Tramacere R, Zappia L (1987a) Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine. Br J Pharmacol 92:153–159
Scarpignato C, Donetti A, Giachetti A, Daniotti S (1987b) The new H2-receptor antagonist mifentidine: current status of the present knowledge. Drugs Future 12 [Suppl 1]:5–22
Schieheer GA, Strike DP (1983) Benzo-fused heterocyclic compounds. European patent 0081955, 22 June
Schunack W, Engler H, Fritschi E (1979) Synthese und H2-antihistaminische Wirkung ringmethylierter Metiamid-Analoga. Arzneimittel forschung 29(4):595–598
Schunack W, Buschauer A, Büyütimkin S et al. (1985) Histamine agonists:chemistry and structure-activity relationships. In: Dahlbom R, Nilsson JLG (eds) Proceedings VIIIth international symposium on medicinal chemistry, vol 2. Swedisch Pharmaceutical, Stockholm, pp 169–182
Schwarz S, Schunack W (1979) Struktur-Wirkungs-Beziehungen bei Histaminanaloga, 18. Mitt. Absolute Konfiguration und histaminartige Wirkung der Enantiomere von 5-Amino-4,5,6,7-tetrahydrobenzimidazol. Arch Pharm (Weinheim) 312:933–939
Schwarz S, Schunack W (1982) Struktur-Wirkungs-Beziehungen bei Histaminanaloga, 24. Mitt. Absolute Konfiguration uńd histaminartige Wirkung der Enantiomere von 4-(2-Aminopropyl)-5-methyl-imidazol. Arch Pharm (Weinheim) 315:674–680
Scott CK, Katz LB, Shriver DA (1986) Pharmacological profile of etintidine, a new histamine H2-receptor antagonist. Arch Int Pharmacodyn 281:5–21
Sellier C, Buschauer A, Elz S, Schunack W (1988) Synthesis and structure-activity relationships of methylated impromidine derivatives and unsaturated analogues. Poster Xth international symposium on medicinal chemistry, Budapest
Shankley NP, Black JW, Ganellin CR, Mitchell RC (1988) Correlation between log Poct/H20 and pKBestimates for a series of muscarinic and histamine H2-receptor antagonists. Br J Pharmacol 94:264–274
Shepherd-Rose AJ, Pendleton RG (1984a) Studies on the properties of 3-N-{3-[3-(l-piperidinomethyl)phenoxy]propyl}amino-4-amino-l,2,5-thiadiazole-1-oxide (L- 643441) as an H2-receptor antagonist in isolated gastric glands. Eur J Pharmacol 105:57–63
Shepherd-Rose AJ, Pendleton RG (1984b) Studies on the H2-receptor antagonism of MK-208 in isolated rabbit gastric glands. Eur J Pharmacol 106:423–426
Smith IR, Cleverly MT, Ganellin CR et al. (1980) Binding of [3H]cimetidine to rat brain tissue. Agents Actions 10:422–426
Smith JL, Gamal MA, Chremos AN, Graham DY (1985) Famotidine, a new H2-receptor antagonist. Effect on parietal, nonparietal, and pepsin secretion in man. Dig Dis Sci 30:308–312
Sorba G, Fruttero R, Calvino R, Gasco A, Orsetti M (1984) Potential histamine H2-receptor antagonists: ranitidine analogues containing “semicarbazono equivalent” groups. Arch Pharm (Weinheim) 317:496–501
Sorba G, Calvino R, Defilippi A, Gasco A, Orsetti M (1985) Potential histamine H2-receptor antagonists: diaminofurazan, a new “urea equivalent” group. Eur J Med Chem 20:571–574
Sorba G, Garrone A, Serafino A, Gasco A, Orsetti M (1986) Potential histamine H2-receptor antagonists: ranitidine analogues containing 2-amino-5(6)-substituted-benzimidazole moieties. Eur J Med Chem 21:391–395
Sorba G, Fruttero R, Gasco A, Orsetti M (1987) Acyclic analogs of classical H2-antagonists: synthesis and activity of dialkylaminoalkyl substituted ethers and oximes. Eur J Med Chem 22:255–259
Speeg KV Jr, Patwardhan RV, Avant GR, Mitchell MC, Schenker S (1982) Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studies in vivo and in vitro in rodents. Gastroenterology 82:89–96
Spengler J-P, Wegner K, Schunack W (1984) Structure-activity relationships in H2-receptor antagonists containing a 4-pyrimidinone moiety. Agents Actions 14:566–568
Stables R, Daly MJ, Humphray JM (1983) Comparison of antisecretory potency and duration of action of the H2-receptor antagonists AH 22216, cimetidine, ranitidine and SK & F 93479 in the dog. Agents Actions 13:166–169
Steffens R, Schunack W (1984) Racemische Histamin-H1Agonisten. Arch Pharm (Weinheim) 317:771–776
Sterk GJ (1987) Studies on histaminergic compounds. PhD thesis, Free University, Amsterdam
Sterk GJ, Van der Goot H, Timmerman H (1984) The H2-agonistic activity of de-N, N-dimethyldimaprit. Eur J Med Chem 19:93–94
Sterk GJ, Van der Goot H, Timmerman H (1986a) Synthesis and histamine H2-activity of a series of corresponding histamine and dimaprit analogues. Arch Pharm (Weinheim) 319:624–630
Sterk GJ, Van der Goot H, Timmerman H (1986b) Non-isosterism between imidazole, guanidino and isothiourea moieties at the H2-receptors. Arch Pharm (Weinheim) 319:1057–1064
Sterk GJ, Van der Goot H, Timmerman H (1986c) The influence of guanidino and isothiourea groups in histaminergic compounds on H2-activity. Agents Actions 18:137–140
Sterk GJ, Van der Schaar MWG, Rademaker B, Van der Goot H, Timmerman H (1986d) Histamine H2-binding on guinea-pig cerebral cortex. Agents Actions 18:231–234
Sterk GJ, Van der Goot H, Timmerman H (1986e) VUF 8405, a potent and relatively easy accessible analogue of the H2-agonist impromidine. Eur J Med Chem 21:305–309
Sterk GJ, Van der Goot H, Timmerman H (1987a) Synthesis and structure-activity relationships of a series of cimetidine and impromidine congeners. Eur J Med Chem 22:427–432
Sterk GJ, Koper J, Van der Goot H, Timmerman H (1987b) A new series of compounds showing Ηχ-antagonistic and H2-agonistic properties; synthesis, in vitro pharmacology and structure-activity relationships. Eur J Med chem 22:491–498
Streett CS, Cimprich RE, Robertson JL (1984) Pathologic findings in the stomachs of rats treated with the H2-receptor antagonist tiotidine. Scand J Gastroenterol 19 [Suppl 101]: 109–117
Szelenyi I, Postius S (1984) The effect of different histamine H2-receptor antagonists on the gastric acid secretion of the isolated whole stomach of the mouse and on the heart rate of spontaneously beating atrium of the guinea-pig. Arzneimittel forschung 34:787–788
Tagaki T, Takeda M, Maeno H (1982) Effect of a new potent H2-blocker, 3-[2-[(diaminomethylene)amino]-4-thiazolyl]methylthio]-N2-sulfamoyl proprionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs. Arch Int Pharmacodyn 256:49–58
Takeda M, Takagi T, Yashima Y, Maeno H (1982) Effect of a new potent H2-blocker, 3-[2-[)diaminomethylene)amino]-4-thiazolyl]methylthio]-N2-sulfamoyl propionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats. Arzneimittel forschung 32:734–737
Tarutani M, Sakuma H, Shiratsuchi K, Mieda M (1985a) Histamine H2-receptor antagonistic action of N -{3-[3-(l-piperidinylmethyl)phenoxy]-propyl}acetoxy-acetamide hydrochloride (TZU-0460). Arzneimittel forschung 35:703–706
Tarutani M, Sakuma H, Shiratsuchi K/ Mieda M (1985b) Effects of N-{3-[3-(l-piperidinylmethyl)phenoxy]propyl}-acetoxy-acetamide hydrochlroide (TZU-0460), a histamine H2-receptor antagonist, on gastric acid secretion and ulcer formation. Arzneimittel forschung 35:844–848
Timmerman H, Haaksma EEJ, Leurs R (1988) Selective ligands for the three types of histamine receptors. In: Melchiorre C, Gianella M (eds) Recent advances in receptor chemistry. Elsevier, Amsterdam, pp 251–273
Tintelnot M (1987) Struktur-Wirkungs-Beziehungen bei Histamin-H2-Rezeptor Antagonisten: Aufbau eines Bindungsstellen-Modells. Arch Pharm (Weinheim) 320:275–279
Torchiana ML, Pendleton RG, Cook PG, Hanson CA, Clineschmidt BV (1983) Apparent irreversible H2-receptor blocking and prolonged gastric antisecretory activities of 3-N-[3-(l-piperidinomethyl)phenoxy]propylamino-4-amino-l,2,5-thiadiazole-l-oxide (L-643,411). J Pharmacol Exp ther 224:514–519
Trumm K-A, Schunack W (1983) Guanidinothiazole mit H2-antihistaminischer Wirkung. Arzneimittel forschung 33:188–190
Trumm K-A, Sattler H-J, Postius S, Szelenyi I, Schunack W (1985) C-2 Basisch substituierte Thiazole mit H2-antagonistischer Wirkung. Arzneimittel forschung 35:573–577
Trumm K-A, Postius S, Szelenyi I, Schunack W (1986) Tetrahydroisochinoline als Bausteine von H2-Antagonisten. Arzneimittel forschung 36:1169–1174
Vitali T, Ferrari C, Bertaccini G, Impicciatore M (1979) Antagonistic properties of N-methyl-N’-[2-(5-ethyl-4-imidazolylmethylthio)ethyl]thiourea. Farmaco [Sci] 34:403–408
Vitali T, Impicciatore M, Plazzi PV, Bordi F, Vitto M (1984) H2-agonisti imidazolici di 2-(2-amino-4-imidazolil)etilamina (2-aminoistamina). Farmaco [Sci] 39:70–80.
Vitali T, Impicciatore M, Plazzi PV, Bordi F, Morini G (1986) Tiazolilalchilamine: sintesi di congeneri delle imidazoliletilamine e loro attività nella secrezione gastrica. Farmaco [Sci] 41:483–498
Wardleworth JM (1984) Guanidine-containing esters as histamine H2-receptor blockers. European patent 0103390 A2, 21 March
Wegner K (1986) Synthese und H2-antagonistische Wirkung von l,3,4-Thiadiazol-2,5-diaminen Arch Pharm (Weinheim) 319:85–88
Wegner K, Fritschi E, Schunack W (1978) Synthese und Pharmakologie α-substituierter Metiamid-Analoga. Arch Pharm (Weinheim) 311:98–103
Wegner K, Krämer I, Schunack W (1987) Synthese und H2-antagonistische Aktivität heteroaromatischer (Thio)Carboxamide und Triazol(thi)on-Derivate des Piperidi-nomethylphenoxypropylamines. Arch Pharm Weinheim 320:108–114
Weinstein H, Mazurek AP, Osman R, Topiol S (1986) Theoretical studies on the activation mechanism of the histamine H2-receptor: the proton transfer between histamine and a receptor model. Mol Pharmacol 29:28–33
Wilkinson CF, Hetnarsky K, Cantwell GP, DiCarlo FJ (1974a) Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo. Biochem Pharmacol 23:2377–2386
Wilkinson CF, Hetnarsky K, Hicks LJ (1974b) Substituted imidazoles as inhibitors of microsomal oxidation and insecticide synergists. Pestic Biochem Physiol 4:299–312
Wilson JA, Johnston DA, Pension J, Wormsley KG (1986) Inhibition of human gastric secretion by ICI 162,846-a new histamine H2-receptor antagonist. Br J Clin Pharmacol 21:685–689
Winzor DJ, Ioannoni B, Reilly PEB (1986) The nature of microsomal monooxygenase inhibition by cimetidine. Biochem Pharmacol 35:2175–2161
Yanagisawa I, Hirata Y, Ishii Y (1984) Synthesis of N-cyano and N-carbamoyl amidine derivatives and their biological activities. J Med Chem 27:849–857
Yanagisawa I, Hirata Y, Ishii Y (1987) Studies on histamine H2-receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives. J Med Chem 30:1787–1793
Yellin TO, Buck SH, Gilman DJ, Jones DF, Wardelworth JM (1979) Tiotidine (ICI 125,211):a new gastric antisecretory agent acting on histamine H2-receptor. Life Sci 25:2001–2009
Young RC, Durant GJ, Emmett JC, Ganellin RC, Graham MJ, Mitchell RC, Prain HD, Roantree ML (1986) Dipole moment in relation to H2-receptor histamine antagonist activity for cimetidine analogues. J Med Chem 29:44–49
Young RC, Ganellin RC, Graham MJ, Mitchell RC, Roantree ML, Tashma Z (1987) Zwitterionic analogues of cimetidine as H2-receptor antagonists. J Med chem 30:1150–1156
Young RC, Mitchell RC, Brown TH, Ganellin RC, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE, Wilks TJ (1988) Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2-receptor histamine antagonists. J Med Chem 31:656–671
Zbaida S, Kariv R, Fischer P, Silman-Greenspan J, Tashma Z (1986) Reaction of cimetidine with Fenton reagent. A biomimetic model for the mixed-function oxidase drug metabolism. Eur J Biochem 154:603–605
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
van der Goot, H., Bast, A., Timmerman, H. (1991). Structural Requirements for Histamine H2 Agonists and H2 Antagonists. In: Uvnäs, B. (eds) Histamine and Histamine Antagonists. Handbook of Experimental Pharmacology, vol 97. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75840-9_27
Download citation
DOI: https://doi.org/10.1007/978-3-642-75840-9_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75842-3
Online ISBN: 978-3-642-75840-9
eBook Packages: Springer Book Archive